can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?
Clicks: 209
ID: 144521
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
209 views
30 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #184 of 207 articles by views in international journal of heat and technology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Receptor tyrosine kinases are known to drive breast cancer progression, particularly in HER2 and basal tumors, the two worst prognosis subtypes. Tumour cells recruit host stromal components, including immune cells, which strongly influence disease progression. This has been studied in human breast cancer and translated to murine models of breast cancer. Stromal immune components including cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, destroy cancer cells through a process termed immune surveillance. Unfortunately, clinically-detectable tumors escape these immune protective effects through their ability to limit the infiltration, activation and/or survival of CTLs in breast tumors. The immunosuppressed state of established tumors limits the success rate of immune-based therapies, and possibly other therapeutic modalities that depend on host immunity. Published studies demonstrate that receptor tyrosine kinases (RTK) facilitate breast cancer progression, in part, by establishing immune suppression. This raises the intriguing possibility that pharmacological RTK inhibitors may be exploited to sensitize breast cancer patients to immune-based therapies.
| Reference Key |
eursini-siegel2013frontierscan
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Josie eUrsini-Siegel |
| Journal | international journal of heat and technology |
| Year | 2013 |
| DOI |
10.3389/fonc.2013.00023
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.